Animal Model Market -Overview

The Animal Model Market Insights by Animal Type (Pigs, Cats, and Mice), Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection), Application (Research and Development and Production and Quality Control), End-User (Research Institutes, Educational Institutes, Pharmaceutical Companies, Contract Research Organizations) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast till 2032

Animal Model Market Size was valued at USD 2.1 billion in 2021 and is projected to grow from USD 2.26 billion in 2022 to USD 4.2 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.1% during the forecast period (2023 - 2032).

The market is anticipated to grow due to the higher demand for precision medicine and improved investigators' awareness of biological similarities between humans and animals. Furthermore, the widespread adoption of genetics in biomedical studies and steadily increasing use of animal models in pre-clinical development by several research facilities and biopharmaceutical industries will further enhance the market development.

Segmental Analysis

The segmental evaluation of the animal model market trends is carried out based on animal type, application, end user, and application. The technology segment of the animal model market consists of CRISPR, embryonic stem cell injection, and microinjection. The application segment of the animal model market consists of production & quality control and research & development. The end-user segment of the animal model market consists of research institutes, pharmaceutical companies, contract research organizations, and educational institutes. The animal type segment of the animal model market consists of cats, pigs, and mice.

Detailed Regional Analysis

The regional examination of the animal market is carried out for the Americas, Asia-Pacific, Europe, Middle East & Africa. The expansion in favourable policies implemented by the US and Canadian governments is helping to raise various funding plans in the research and development activities, which is one of the primary reasons for this tremendous growth. In addition, there has been a significant increase in the number of investments coming in. As a result, the animal model market in this region is expected to grow at the fastest rate. Asia-Pacific offers excellent advantages for key players in the animal model market, owing to an increment in the number of initiatives and public spending for overall R&D of medicines using animal models and an expansion in the implications of mouse clinical trials (MCTs) for more predicting outcomes.

Competitive Analysis

The ability to stay in touch with end-users while effectively expanding the comprehensive footprint is poised to grow as the main goal for several market stakeholders. A need to pool viable alliances is predicted to become more apparent in the market. The market is likely to be defined by the governments' agreed-upon measures for revitalizing the entire market. Market competition is expected to be the driving force behind several global market growth policy restructurings. In the projected period, changes in manufacturing and distribution tactics are projected to augment the market on a global scale. The transition to a more effective working environment is set to change the established working method during the period considered. Developing a better service delivery channel is expected to define the global market's subsequent phase of development. The market is supposed to pick up on the impacts of the current state of affairs presently.

The distinguished players in the animal model market are GenOway S.A. (France), Envigo (US), Transgenic, Inc. (Japan), Charles River Laboratories (UK), Taconic Laboratories (UK), SAGE Labs (US), Crown Bioscience Inc. (US), Janvier Labs (France), Harbor Antibodies Bv (A Subsidiary of Harbor BioMed) (Massachusetts) and Horizon Discovery (England).

Industry Updates:

Nov 2021 The Boston firm, which develops and manufactures next-generation in vitro models that enable researchers to duplicate and study human biology and disease, described Zo-CM2 as a "pivotal advancement." Platform advancements broaden applicability and reliability for researchers and drug makers through remote operation, support, and continual software updates. The technique, aimed at industry, university academics, and government agencies, allows professionals to comprehend better and anticipate medication reactions than is achievable with traditional cell culture or animal-based methodologies.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com